Zhong zhong Kan yao 021
On February 15th nasdaq approved the listing of Canadian cannabis growers and rural farms.North America is set to welcome its seventh marijuana company to the market.Country farms is one of the largest and longest-running vertically integrated greenhouse growers in North America, with a market capitalization of $366 million.
With more and more cannabis companies listed in North America, which ones are competitive?What does the performance of these public companies portend for the marijuana market?Let's look at the companies first, and then we'll do the analysis.
Zhong zhong has always been highly concerned about industrial cannabis. Two reports have been published in the last two days, which have been widely concerned by the industry. They are:
On May 1, 2013, the stock market opened at 8.90, with a peak of 179.65. The latest closing price was 150.49, with a market value of 4.6 billion dollars.
Founded in 1998 and headquartered in Cambridge, England, it grows about 20 tons of marijuana a year in a greenhouse the size of a football field.Focusing on the application of cannabinoid products in the field of diseases, the company has established a world-leading position in the development of cannabinoid therapy, and has registered the patents of cannabinoid for the treatment of epilepsy, mental illness, cancer, inflammation, diabetes and multiple sclerosis, as well as the process of extracting hemp extract with supercritical fluid.
GW has successfully developed the world's first prescription drug from the cannabis plant, called Sativex, which contains THC and CBD, and has been approved in 25 countries outside the United States for the treatment of spasms caused by multiple sclerosis.
On June 26, 2018, FDA approved GW to develop an oral preparation of purified cannabidiol (CBD) for sale to treat two types of epilepsy in children.The drug, called Epidiolex, is also the first CBD drug approved by the FDA.
At present, GW is continuing to research and develop Sativex, tuberous sclerosis complex and other phase iii trials, glioblastoma is conducting phase ii trials, and neonatal hypoxic-ischemic encephalopathy (NHIE) intravenous injection of CBD is planned to complete phase I trials.
Revenue for the third quarter of 2018 was $12.7 million, up 47.67 percent from a year earlier, according to the company's financial disclosure.
The company went public on February 27, 2018. It opened at $8.24 on its first day of trading, with a top price of $25.10. It closed at $21.29 on its last day of trading, with a market value of $3.8 billion.
Cronos Group has two 126-acre cultivation bases in Canada, mainly for the cultivation, production and sales of medical marijuana, and its products have been exported to 35 countries in Europe and Asia.
In addition, there are planting bases in Colombia and Israel.Colombia's 50-50 joint venture, which grows, produces and exports marijuana-based medicinal and consumer products for the Latin American and global markets, has 207 acres in quintana marca.In the Israeli planting base, high quality medical marijuana can be produced due to ideal climatic conditions, and the estimated cost is between us $0.40 and us $0.50 / g. In the first stage, the annual production capacity of marijuana is 5,000 kg, and in the second stage, the annual production capacity is increased to 24,000 kg.A 50-50 joint venture in Melbourne, Australia, recently received a licence to grow and research cannabis with an estimated annual capacity of 2,000kg.
Meanwhile, in Poland, it has established a strategic distribution partnership with Delfarma.Founded in 2004, Delfarma is a private pharmaceutical wholesaler and the first polish company to introduce international parallel drug imports from eea countries.
Delfarma distributes directly to more than 5,000 pharmacies and more than 200 hospitals, accounting for about 40 per cent of Poland's domestic market.In Germany, pohl-boskamp signed an exclusive supply agreement.Pohl-boskamp is an international pharmaceutical manufacturer and supplier established in 1835. Pohl distributes products to more than 12,000 German pharmacies.
Canopy Growth Corporation
Listed on May 24, 2018, with the opening price of 30.85, the highest price of 56.89, the latest closing price of 47.56, and the market value of 10.6 billion dollars.
Canopy Growth became the first publicly traded marijuana company in North America in April 2014.The company's business ranges from cannabis cultivation to the production of cannabis extracts using the most advanced supercritical fluid CO2 extraction technology, the production of different proportions of THC and CBD sesame oil products, soft capsules, and the sale of dried flowers.
Among its subsidiaries, Canopy Animal Health, a wholly-owned subsidiary, focuses on making Health products based on marijuana for companion animals.Storz&Bickel is the only manufacturer and designer of medically approved evaporators in the world.The ebbu team conducts thc-rich hemp genetic breeding programs and the hemp infused energy drinks.
At the same time, Canopy Growth has a relationship with four companies to develop marijuana drugs.Apollo, a subsidiary company, has been conducting clinical research on chronic pain since 2014.Entourage Phytolab, a subsidiary, aims to develop cannabis-based drugs for the Brazilian and international markets.Scientus Pharma, with a 9.8% stake, is a vertically integrated licensed biopharmaceutical distributor focused on the development and commercialization of pharmaceutical grade cannabinoid derivatives.
According to Canopy Growth's latest 2018 earnings report, total sales were $98 million;Net income was $83 million, including $74.9 million for the marijuana business.Canadian recreational marijuana revenue totaled $71.6 million.Total medical marijuana revenue: $18.6 million.From the product point of view, the new product soft capsule growth is fast, about 30% and 42% of leisure and medical sales are contributed by the sesame oil, including soft capsule.
Canopy Growth has also made a series of expansions since going public, adding retail outlets in places like Tokyo to prepare for the launch of marijuana ingredients and drinks later in 2019.On January 14, New York state obtained the hemp processing and production license, and planned to invest $100 million to $150 million to build the hemp industrial park in New York.
Last year constellation, a beer giant, invested $4 billion in Canopy Growth to develop a cannabis drink.
The company went public on July 19, 2018, with an opening price of 23.05 yuan on the first day, a maximum of 300 yuan, and a latest closing price of 76.49 yuan, with a market value of 7.126 billion us dollars.
Tilray is a GMP certified medical marijuana producer that has developed strains to meet the needs of patients, including indica rice, alfalfa, hybrids and cbd-rich varieties. There are two main forms of medical marijuana: extracts and dried flowers, each of which can be administered or consumed in a variety of ways.
Tilray describes itself as a global pioneer in medical marijuana, offering products in 12 countries and territories, with operations in Australia and New Zealand, Canada, Germany, Latin America and Portugal.At present, the ongoing Tilray multiple marijuana drug clinical trials, and the university of Sydney and new south wales government cooperation of cannabinoid nausea and vomiting caused by chemotherapy to 2 and 3 stage of clinical trials have been working with children's hospital in Toronto epilepsy syndrome in clinical trials in the second stage, cooperation with the university of British Columbia, Canada post traumatic stress disorder to phase 2 clinical trials.
On December 18, 2018, Tilray announced a cooperation agreement with pharmaceutical giant novartis group. The core content of the agreement is that novartis group supports Tilray's global commercialization of non-smoking, non-combustible medical marijuana products and cooperates to develop new and innovative medical marijuana products.
On December 19, 2018, AB and Tilray, the world's leading brewers, announced a canadian-wide collaboration to study non-alcoholic beverages containing tetrahydrocannabinol (THC) and cannabinol (CBD).As part of the deal, each company invested $50 million in research.
On January 15, Tilray and ABG signed a long-term revenue-sharing agreement under which Tilray becomes the preferred supplier of active cannabinoid ingredients to ABG. Tilray will initially pay ABG $100 million and up to $250 million in cash and stock to receive 49% of the net proceeds from ABG branded cannabis products.ABG has 100,000 global retail outlets.
On November 13, 2018, Tilray announced its financial results for the third quarter of 2018, with revenue up 85.8 percent year on year.Medical marijuana products sold totaled 1,613 kilograms, more than tripling year-on-year.
On October 23, 2018, the listing opened at $7.28, with a maximum opening price of $8.63. The last closing price was $7.05, with a market value of $6.789 billion.
Aurora has an annual production capacity of more than 50 tons and operates in 23 countries on five continents. On February 11, 2019, the company announced that it had completed the first export of sesame oil to the United Kingdom and distributed it from pharmacies.There are 8 plants in production and 3 under construction, covering the whole industrial chain of hemp, including a hemp laboratory, the largest organic hemp and hemp product processing plant in Europe, greenhouse project company, the largest import and export of medical hemp in the eu, and a medical hemp pharmaceutical factory.
Aurora reported on February 11 that its operating results for the second quarter ended December 31, 2018, were driven by strong performance in the Canadian consumer market for cannabis extracts (including cannabis oil and capsules), with sales of $21.6 million and net income of $54.2 million.In the international medical market, sales were $26 million, with revenue up 8% and sales up 23%.
Aurora is currently producing about 12 tons per year and is expected to exceed 15 tons by March 31, 2019, according to the planting Chambers approved by the Canadian ministry of health.Meanwhile, it will focus on the development of high-margin products, launch Canada's first legal vape-ready CBD oil box, and start selling soft capsules of marijuana.Aurora is also actively pursuing cannabis drugs, with 40 clinical trials and case studies completed or ongoing, seven ongoing preclinical trials, and six new partnerships with leading academic development institutions.
Aurora, meanwhile, has made a series of acquisitions since going public.On November 22, 2018, Aurora acquired south america-based ICC Labs Inc., a leading manufacturer and distributor of CBD and cannabinoid products, with a market share of more than 70% in Uruguay and a license to produce medical marijuana in Colombia.On January 31, 2019, the company signed the final agreement to acquire whistler.Whistler is one of Canada's most iconic marijuana brands.On December 10, 2018, the company signed a letter of intent to acquire Farmacias, Mexico's first and only federally licensed importer of THC raw materials, which manufactures, stores and distributes medical marijuana products containing more than 1% THC.
According to a report published in mid-september by BNN Bloomberg, Coca-Cola is considering developing a cannabis drink (containing the non-psychoactive ingredient, CBD) for medical use and is in preliminary discussions with Aurora.
It went public on November 2, 2018, with an opening price of 11.75 yuan on the first day, a top of 14.29 yuan, and a latest closing price of 9.60 yuan, with a market value of 2.233 billion yuan.
Canada's third largest cannabis company.On January 11, Aphria reported its second-quarter results for November 30, 2018.Adjusted gross profit was $10.2 million.Adjusted gross margin was 47 per cent of net income, compared with 64 per cent in the previous quarter.This is due to lower effective selling prices in the adult market as well as temporary reductions in production and higher production cost automation associated with facility expansion and implementation.The increase in revenue for the quarter was due to a 92 per cent increase in kilogram-equivalent sales of cannabis and a $1.6 million increase in non-cannabis international sales.The adult use market sells the dry bud proportion to be higher.
Aphria is currently expanding or renovating the site and introducing industrial scale horticultural production technology to the automated process of cannabis cultivation.
On jan 9, it bought german-based CC Pharma, which distributes drugs and medical marijuana to more than 13,000 pharmacies.The board expressed optimism about the recently announced alliance and acquisition of highly strategic licensing and operations in the most attractive emerging cannabis markets in Latin America and the Caribbean, including Colombia, Argentina, Paraguay and Jamaica.
On February 1st Aphria exported cuttings from four varieties of hemp to Schroll, a Danish company, to expand its market position in Europe.
Aphria's board said the current priority was to expand production and automate production, which is currently at 3.5 tonnes and is expected to reach 25.50 tonnes by the end of 2019.
In January, the us green growth brand launched a hostile bid for Aphria, which was rejected by its board with no result.
With high homogeneity, future competition focuses on food, beverage and medicine
All the above 6 listed hemp companies are engaged in cultivation. Except GW cultivation, the other 5 companies are engaged in cultivation and sales of dried flowers, hemp extract oil and capsules.
Of the six, only plantation and sales companies have seen flat share prices, such as Aurora, which has had a flat share price curve since its ipo, and Aphria, which has broken its ipo price.So not all marijuana stocks are good for investors.There have even been warnings from us investment houses to short some cannabis stocks.
Disclaimer: this article is from tencent news client we media, does not represent the views and positions of qq.com